Emedastine Difumarate(레미코트)의 통년성 알레르기 비염환자에 대한 임상 : 이중맹검 군간 비교시험 = Clinical Effect of Emedastine Difumarate in Perennial Allergic Rhinitis Patients

다국어 초록 (Multilingual Abstract)

Emedastine difumarate has anti allergic effect and stabilizing effect on mast cell in animal experiment. A double-blind placebo-controlled study was carried out in 52 patients with perennial allergic rhinitis to assess the effectiveness, safety and usefulness of emedastine difumarate. Emedastine difumarate(2 mg per single dose, twice a day) was given for two weeks. Patients were randomly allocated into two groups, one active ingredient(E group, 34 patients) and the other placebo(P group, 18 patients). Most symptoms and physical findings were more improved in the second week compared with the first week. The subjective symptomatic improvement was statistically significant(P<0.05) in sneezing and rhino rhea. With respect to the global safety rate, 93.4 % of the E group was assessed as <safe>, and there was no significant differences between E and P group. The clinical usefulness (excluding no change) was 88.3 % for the E group, significant differences being noted between the two groups(p<0.01)
In conclusion, Emedastine difumarate is an effective drug for management of perennial allergic rhinitis.